Im saying that offering incentives to extend the warrants post being unblinded would not be an issue as long as the terms did not indicate if the trial data that they were unblinded to were good or bad.
If the data were bad then they would indeed leave themselves open to future law suits but if they were good I cant imagine law suits flying can you ?
If the driver of the extensions was to indeed give the share price a chance following release of data then that comes under their primary responsibility which is of course ... altogether now 'create shareholder value !!'